Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are widely used in Uruguay to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The market for these drugs has been growing steadily in recent years due to various factors.
Customer preferences: Uruguayan customers prefer bronchodilator drugs that provide quick relief from respiratory symptoms such as shortness of breath and wheezing. They also prefer drugs that are easy to use and have minimal side effects. Customers tend to trust well-established brands and are willing to pay a premium for them.
Trends in the market: The Bronchodilator Drugs market in Uruguay has been growing due to various factors such as an increase in the prevalence of respiratory diseases, an aging population, and a rise in air pollution levels. The market is also being driven by the availability of new and innovative drugs that are more effective and have fewer side effects than traditional drugs. The trend towards self-medication is also contributing to the growth of the market, as more people are buying over-the-counter bronchodilator drugs.
Local special circumstances: Uruguay has a high prevalence of respiratory diseases, with asthma affecting approximately 10% of the population. This is partly due to the country's high levels of air pollution, which are caused by factors such as industrial activity, traffic, and the burning of fossil fuels. The country also has a high smoking rate, which further exacerbates respiratory problems.
Underlying macroeconomic factors: Uruguay has a stable economy with a growing middle class, which is driving demand for healthcare products and services. The country has a well-developed healthcare system that provides universal coverage, which means that bronchodilator drugs are accessible to a large segment of the population. The government also regulates drug prices, which helps to keep prices affordable for consumers. However, the country's small market size and limited healthcare budget may limit the growth of the Bronchodilator Drugs market in the future.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
